Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 3185-3188

  Bersanelli, Melissa ^a   Tiseo, Marcello ^a   Artioli, Fabrizio ^b   Lucchi, Leonardo ^c   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b Carpi e Mirandola Hospital   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Afatinib; Dialysis; EGFR TKI; Gefitinib; Hemodialysis; NSCLC; Renal failure

Indexed keywords

AFATINIB; CISPLATIN; GEFITINIB; GEMCITABINE; HAPTOGLOBIN; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; BONE LESION; BONE PAIN; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; COMPASSIONATE USE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEMODIALYSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG ADENOCARCINOMA; MAINTENANCE THERAPY; MEDIASTINUM LYMPH NODE; MIDDLE AGED; MORNING DOSAGE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; PROTEIN BLOOD LEVEL; SIDE EFFECT; THROMBOCYTOPENIA; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE; VOMITING; DIALYSIS; EGFR-TKI; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NSCLC; PATHOLOGY; PROGNOSIS; RENAL REPLACEMENT THERAPY;

AFATINIB; DIALYSIS; EGFR-TKI; GEFITINIB; HEMODIALYSIS; NSCLC; RENAL FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; QUINAZOLINES; RENAL DIALYSIS;

EID: 84906303119     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P and Deray G (Renal Insufficiency and Cancer Medications Study Group): Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6): 1376-1384, 2007.
2. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P and Deray G (IRMA study group): Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187(1): 69-74, 2009.
3. Janus N, Launay-Vacher V, Thyss A, Boulanger H, Moranne O, Islam MS, Durande JP, Ducret M, Juillard L, Soltani Z, Motte G, Rottembourg J, Deray G and Thariat J: Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24(2): 501-507, 2013.
4. U.S. Department of Health & Human Services. U.S. Food and Drug Administration. Afatinib. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm
5. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorization). Giotrif (afatinib). 25 July 2013, EMA/CHMP/447957/2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002280/h uman-med-001698.jsp&mid=WC0b01ac058001d124.
6. Sequist LV, Yang JCH, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov s, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M and Schuler M: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 3335-3341, 2013.
7. Wu YL, Zhou C, Hu CP, Feng J, Lu s, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y and Geater SR: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open label, randomised phase 3 trial. Lancet Oncol 15(2): 213-222, 2014.
8. Highlights of prescribing information. GILOTRIFTM (afatinib) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201292s000lbl.pdf
9. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W and Vigil J: A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85(9): 2023-2032, 1999.
10. Walter RB, Joerger M and Pestalozzi BC: Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 40(4): E16, 2002.
11. Saif MW and McGee PJ: Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP 6(4): 369-374, 2005.
12. Glezerman I, Kris MG, Miller V, Seshan S and Flombaum CD: Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 71(2): 130-9, 2009.
13. Graas MP, Houbiers G, Demolin G, Stultiens A and Focan C: Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication? Rev Med Liege 67(12): 644-648, 2012.
14. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, OU SH, Yu CJ, Chang JC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC and Miller VA: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-lung 2): a phase II trial. Lancet Oncol 13(5): 539-548, 2012.
15. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM and Yang JC: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13(5): e186, 2012.
16. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M and Yamamoto N: LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31(27): 3335-3341, 2013.
17. Rossi A, Maione P, Del Gaizo F, Guerriero C, Castaldo V and Gridelli C: Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 47(3): 421-423, 2005.
18. Shinagawa N, Koiki Y, Hajime A, Jun A, Takayuki I and Masaharu N: Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer 58: 422-424, 2007.
19. Del Conte A, Minatel E, Schinella D, Baresic T, Basso MMS and Lumachi F: Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Res 34(1): 319-322, 2014.
20. Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH, Fujita S, Irisa K, Sakamori Y, Mio T, Inui K and Mishima M: Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 5(5): 601-5, 2010.
21. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM and Ratain MJ: Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25(21): 3055-60, 2007.
22. Gridelli C, Maione P, Galetta D and Rossi A: Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. J Thorac Oncol 2(1): 96-98, 2007.